Bio-Rad's Kallestad Anti-CCP II autoimmune EIA assay uses a second-generation peptide with improved sensitivity to aid in the diagnosis and management of rheumatoid arthritis (RA), including RA diagnosis in early synovitis patients. It also assists in the differential diagnosis of RA from other connective tissue diseases such as systemic lupus erythematosus (SLE) and in diagnosis confirmation of seronegative polyarthritis.
The Anti-CCP II EIA is based on the detection of autoantibodies against the cyclic-citrullinated peptide containing modified arginine residues in human serum or plasma. In the quantitative protocol, the antibody concentration in an unknown sample can be estimated by interpolation from a dose response curve based on reference standards. In the qualitative protocol, the response measured in the unknown sample is compared to the known concentration of the reference control.